Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
2024年7月22日 - 9:03PM
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company")
(Nasdaq: CPRX), a commercial-stage biopharmaceutical company
focused on in-licensing, developing, and commercializing novel
medicines for patients living with rare and difficult-to-treat
diseases, today announced that it will release its second quarter
2024 financial results after the market close on Wednesday,
August 7, 2024.
Catalyst's management team will host a
conference call and webcast on Thursday, August 8, 2024,
at 8:30 AM ET to discuss the Company's financial results and
provide a business update.
Conference Call & Webcast
Details
Date:Time:US/Canada
Dial-in Number:International Dial-in
Number: |
August 8,
20248:30 AM ET(877) 407-8912 (201) 689-8059 |
The webcast will be accessible under the
Investors section on the Company's website at
www.catalystpharma.com. A webcast replay will be available on the
Catalyst website for at least 30 days following the date of the
event.
About Catalyst Pharmaceuticals,
Inc.
With exceptional patient focus, Catalyst is
committed to developing and commercializing innovative
first-in-class medicines that address rare and difficult-to-treat
diseases. Catalyst's flagship U.S. commercial product is
FIRDAPSE® (amifampridine) Tablets 10 mg, approved for the treatment
of Lambert-Eaton myasthenic syndrome ("LEMS") in adults
and pediatric patients 6 years of age and older. In January
2023, Catalyst acquired the U.S. commercial rights to
FYCOMPA® (perampanel) CIII, a prescription medicine approved in
people with epilepsy aged four and older alone or with other
medicines to treat partial-onset seizures with or without
secondarily generalized seizures and with other medicines to treat
primary generalized tonic-clonic seizures for people with epilepsy
aged 12 and older. Further, Canada's national healthcare
regulatory agency, Health Canada, has approved the use of
FIRDAPSE for the treatment of adult patients
in Canada with LEMS. On July 18, 2023, Catalyst
acquired an exclusive license for North America for
AGAMREE® (vamorolone) oral suspension 40 mg/mL, a novel
corticosteroid treatment for Duchenne Muscular Dystrophy. AGAMREE
previously received FDA Orphan Drug and Fast Track designations and
was approved by the FDA for commercialization in
the U.S. on October 26, 2023. AGAMREE became
commercially available by prescription in the U.S. on March 13,
2024.
For more information about Catalyst
Pharmaceuticals, Inc., please visit the Company's website
at www.catalystpharma.com. For Full Prescribing and Safety
Information for FIRDAPSE®, please visit www.firdapse.com. For
Full Prescribing Information, including Boxed WARNING for FYCOMPA®,
please visit www.fycompa.com. For Full Prescribing Information
for AGAMREE®, please visit www.agamree.com.
Forward-Looking Statements
This press release contains forward-looking
statements, as that term is defined in the Private Securities
Litigation Reform Act of 1995. Forward-looking statements involve
known and unknown risks and uncertainties, which may cause
Catalyst's actual results in future periods to differ materially
from forecasted results. A number of factors, including those
factors described in Catalyst's Annual Report on Form 10-K for the
fiscal year 2023 and its other filings with the U.S.
Securities and Exchange Commission ("SEC"), could adversely
affect Catalyst. Copies of Catalyst's filings with
the SEC are available from the SEC, may be found on
Catalyst's website, or may be obtained upon request from Catalyst.
Catalyst does not undertake any obligation to update the
information contained herein, which speaks only as of this
date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Contact
Mary Coleman, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
mcoleman@catalystpharma.com
Media Contact
David Schull, Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
過去 株価チャート
から 6 2024 まで 7 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
過去 株価チャート
から 7 2023 まで 7 2024